Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Operations: 2018-2024

Historic Cash from Operations for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$200.3 million.

  • Allogene Therapeutics' Cash from Operations rose 32.70% to -$29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.3 million, marking a year-over-year increase of 27.13%. This contributed to the annual value of -$200.3 million for FY2024, which is 15.75% up from last year.
  • Per Allogene Therapeutics' latest filing, its Cash from Operations stood at -$200.3 million for FY2024, which was up 15.75% from -$237.7 million recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' Cash from Operations peaked at -$115.1 million during FY2020, and registered a low of -$237.7 million during FY2023.
  • In the last 3 years, Allogene Therapeutics' Cash from Operations had a median value of -$220.5 million in 2022 and averaged -$219.5 million.
  • Per our database at Business Quant, Allogene Therapeutics' Cash from Operations increased by 16.20% in 2020 and then crashed by 60.58% in 2021.
  • Allogene Therapeutics' Cash from Operations (Yearly) stood at -$115.1 million in 2020, then plummeted by 60.58% to -$184.8 million in 2021, then declined by 19.32% to -$220.5 million in 2022, then dropped by 7.81% to -$237.7 million in 2023, then rose by 15.75% to -$200.3 million in 2024.